Secobarbital

Summary

Secobarbital (CHEMBL447) is an approved small-molecule GABA modulator (ATC N05CA06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA06
• Chemistry: 238.28 Da · C12H18N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL447
Name	Secobarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5193
ChEBI	CHEBI:9073
ATC	N05CA06
Molecular formula	C12H18N2O3
Molecular weight	238.28
InChIKey	KQPKPCNLIDLUMF-UHFFFAOYSA-N

SMILES: CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C

IUPAC name: 5-pentan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione

ChEBI definition: A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.

Pharmacological roles (ChEBI): anaesthesia adjuvant, GABA modulator, sedative.

Also known as: (rs)-secobarbital, Evronal, Hypotrol, Immenox, Meballymal, Quinalbarbital, Secobarbital, Secobarbital cii, Secobarbital sodium free acid, Secobarbitone, Seconal, Somatarax

Parent form; salt/anhydrous children: CHEMBL1200903

Patent coverage: 3,050 distinct patent families (11,739 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,738 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Matrix metalloproteinase-9.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MMP9	5.58	IC50	2643	nM	CHEMBL_ACT_7798729

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).